Brazil's Anvisa probes 13 sudden blindness cases linked to weight-loss pens

Brazil's health regulator Anvisa is investigating 13 reports of rare optic nerve injury (sudden blindness) associated with weight-loss pens, likely GLP-1 agonists. The cases are under review to determine causality; no regulatory action has been announced yet. This could signal a new safety signal for a widely used drug class, with potential market implications if confirmed.